Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1651 to 1675 of 2545

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Pegaspargase for treating acute lymphoblastic leukaemiaTA408
Secukinumab for treating active ankylosing spondylitisTA407
Miniature lens system implantation for advanced age-related macular degenerationHTG418
Multimorbidity: clinical assessment and managementNG56
Intravenous fluid therapy in children and young people in hospitalQS131
Social care for older people with multiple long-term conditionsQS132
Harmful sexual behaviour among children and young peopleNG55
QuikRead go for C-reactive protein testing in primary careMIB78
FLEXISEQ for osteoarthritisMIB80
Alere Afinion CRP for C-reactive protein testing in primary careMIB81
Mental health problems in people with learning disabilities: prevention, assessment and managementNG54
ContraceptionQS129
Transition between inpatient mental health settings and community or care home settingsNG53
Stable angina: managementCG126
Acute upper gastrointestinal bleeding in over 16s: managementCG141
Axxent electronic brachytherapy system for early stage breast cancerMIB76
OSNA for colon cancer stagingMIB77
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxelTA391
Bosutinib for previously treated chronic myeloid leukaemiaTA401
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatinTA402
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancerTA403
Degarelix for treating advanced hormone-dependent prostate cancerTA404
Trifluridine–tipiracil for previously treated metastatic colorectal cancerTA405
Early years: promoting health and wellbeing in under 5sQS128
Palliative care for adults: strong opioids for pain reliefCG140

Results per page

  1. 10
  2. 25
  3. 50
  4. All